Unlearn appoints Krates Ng as Chief Technology Officer to lead next phase of technological and operational expansion.

DELRAY BEACH, Fla., Dec. 17, 2024 /PRNewswire/ -- The global artificial intelligence in clinical trials market is forecasted to grow steadily from US$1.20 billion in 2023 to US$1.35 billion in 2024, ultimately reaching an impressive US$2.74 billion by 2030, driven by a robust CAGR of 12.4%. Some of the key elements fueling the expansion of the AI in clinical trials market, are the high rate of clinical trial failures, the increasing need of anticipating drug pharmacokinetics, pharmacodynamics, and management of toxicity. According to a research article published by the National Library of Medicine in February 2022, the drug discovery and development process takes about 10-15 years for a new drug to be approved for clinical use. And 90% of the drug candidates fail during the phases I, II, and III of clinical trials and drug approvals. The reasons that may result in failure include but not limited to effectiveness in a clinical setting, high levels of toxicity that cannot be managed, suboptimal drug-like characteristics, a lack of real commercial drivers, and poor strategic design